Back to Search
AMBER HUTCHISON, PHARMD, BCPS
PHARMD, BCPS
Pharmacotherapy Pharmacist
NPI: 1780091199Individual
Specialties, Licenses & Credentials
Pharmacotherapy PharmacistPrimary
Pharmacist — Pharmacotherapy
Code: 1835P1200X
15690(AL)PS43002(FL)
Research & Publications (20)
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
PMID 19281739·Clin Nephrol·2009
1-meta
Physical activity behavior change interventions based on the transtheoretical model: a systematic review.
PMID 18607007·Health Educ Behav·2009
1-meta
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
PMID 18577536·Nephrol Dial Transplant·2008
3-trial
Non-invasive positive pressure ventilation in the preterm neonate: reducing endotrauma and the incidence of bronchopulmonary dysplasia.
PMID 17768159·Arch Dis Child Fetal Neonatal Ed·2008
6-review
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
PMID 18667837·Nephron Clin Pract·2008
3-trial
The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries.
PMID 16846678·Eur Urol·2007
4-observational
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
PMID 16224198·Nephron Clin Pract·2006
4-observational
Characteristics of patients presenting with LUTS/BPH in six European countries.
PMID 16782265·Eur Urol·2006
4-observational
Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
PMID 15809508·Nephron Clin Pract·2005
4-observational
Improving phosphate-binder therapy as a way forward.
PMID 15126650·Nephrol Dial Transplant·2004
6-review
Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
PMID 15199195·Nephrol Dial Transplant·2004
3-trial
Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
PMID 19158369·Clin J Am Soc Nephrol·2009
3-trial
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
PMID 19222734·J Ren Care·2009
6-review
Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist.
PMID 18753409·J Pharmacol Exp Ther·2008
7-preclinical
Exploring patient-physician communication in breast cancer care for African American women following primary treatment.
PMID 18765331·Oncol Nurs Forum·2008
4-observational
Knowledge of carbohydrate consumption does not alter natural killer cell activity following an acute bout of high-intensity aerobic exercise.
PMID 18923577·Appl Physiol Nutr Metab·2008
2-rct
Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.
PMID 19209270·Ther Clin Risk Manag·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4201F WALKER BUILDING
AUBURN UNIVERSITY, AL 36849 - Phone
- (334) 844-8401
Quick Facts
- NPI
- 1780091199
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile